nodes	percent_of_prediction	percent_of_DWPC	metapath
Procainamide—SLC22A1—hematologic cancer	0.237	1	CbGaD
Procainamide—SLC22A3—Melphalan—hematologic cancer	0.0691	0.161	CbGbCtD
Procainamide—SLC22A2—Daunorubicin—hematologic cancer	0.029	0.0672	CbGbCtD
Procainamide—SLC22A2—Cytarabine—hematologic cancer	0.0255	0.0593	CbGbCtD
Procainamide—ACHE—Irinotecan—hematologic cancer	0.0241	0.056	CbGbCtD
Procainamide—SLC22A2—Cladribine—hematologic cancer	0.0241	0.056	CbGbCtD
Procainamide—SLC22A3—Irinotecan—hematologic cancer	0.0234	0.0544	CbGbCtD
Procainamide—SLC22A1—Cytarabine—hematologic cancer	0.0222	0.0515	CbGbCtD
Procainamide—SLC22A2—Imatinib—hematologic cancer	0.0222	0.0515	CbGbCtD
Procainamide—SLC22A1—Cladribine—hematologic cancer	0.021	0.0487	CbGbCtD
Procainamide—SLC22A3—Vincristine—hematologic cancer	0.0205	0.0475	CbGbCtD
Procainamide—SLC22A1—Imatinib—hematologic cancer	0.0193	0.0447	CbGbCtD
Procainamide—BCHE—Triamcinolone—hematologic cancer	0.0192	0.0445	CbGbCtD
Procainamide—BCHE—Irinotecan—hematologic cancer	0.0145	0.0337	CbGbCtD
Procainamide—SLC22A2—Vinblastine—hematologic cancer	0.0123	0.0286	CbGbCtD
Procainamide—BCHE—Cisplatin—hematologic cancer	0.0118	0.0275	CbGbCtD
Procainamide—CYP2D6—Lomustine—hematologic cancer	0.0115	0.0267	CbGbCtD
Procainamide—SLC22A2—Cisplatin—hematologic cancer	0.0113	0.0262	CbGbCtD
Procainamide—CYP2D6—Idarubicin—hematologic cancer	0.0103	0.0238	CbGbCtD
Procainamide—CYP2D6—Hydroxyurea—hematologic cancer	0.00873	0.0203	CbGbCtD
Procainamide—CYP2D6—Bortezomib—hematologic cancer	0.00759	0.0176	CbGbCtD
Procainamide—CYP2D6—Imatinib—hematologic cancer	0.00556	0.0129	CbGbCtD
Procainamide—CYP2D6—Nilotinib—hematologic cancer	0.00506	0.0117	CbGbCtD
Procainamide—CYP2D6—Vinorelbine—hematologic cancer	0.00501	0.0116	CbGbCtD
Procainamide—CYP2D6—Vinblastine—hematologic cancer	0.00309	0.00717	CbGbCtD
Procainamide—CYP2D6—Dexamethasone—hematologic cancer	0.00229	0.00531	CbGbCtD
Procainamide—CYP2D6—Doxorubicin—hematologic cancer	0.0019	0.00441	CbGbCtD
Procainamide—DNMT1—hematopoietic system—hematologic cancer	0.00157	0.0433	CbGeAlD
Procainamide—SCN2A—hematopoietic system—hematologic cancer	0.00127	0.0349	CbGeAlD
Procainamide—SCN10A—hematopoietic system—hematologic cancer	0.00122	0.0336	CbGeAlD
Procainamide—DNMT1—gonad—hematologic cancer	0.0012	0.033	CbGeAlD
Procainamide—SCN7A—lung—hematologic cancer	0.00119	0.0328	CbGeAlD
Procainamide—SCN7A—testis—hematologic cancer	0.00112	0.0309	CbGeAlD
Procainamide—DNMT1—blood—hematologic cancer	0.00104	0.0287	CbGeAlD
Procainamide—DNMT1—bone marrow—hematologic cancer	0.00101	0.0278	CbGeAlD
Procainamide—SCN8A—testis—hematologic cancer	0.001	0.0276	CbGeAlD
Procainamide—Lucanthone—TOP1—hematologic cancer	0.000972	0.178	CrCbGaD
Procainamide—SCN9A—lung—hematologic cancer	0.000931	0.0257	CbGeAlD
Procainamide—DNMT1—lung—hematologic cancer	0.000913	0.0252	CbGeAlD
Procainamide—SLC22A3—hematopoietic system—hematologic cancer	0.000887	0.0244	CbGeAlD
Procainamide—SCN9A—testis—hematologic cancer	0.000879	0.0242	CbGeAlD
Procainamide—DNMT1—testis—hematologic cancer	0.000862	0.0238	CbGeAlD
Procainamide—SCN2A—blood—hematologic cancer	0.000839	0.0231	CbGeAlD
Procainamide—SCN7A—lymph node—hematologic cancer	0.000813	0.0224	CbGeAlD
Procainamide—SCN10A—blood—hematologic cancer	0.000809	0.0223	CbGeAlD
Procainamide—SCN1A—lung—hematologic cancer	0.000801	0.0221	CbGeAlD
Procainamide—SCN4A—testis—hematologic cancer	0.000784	0.0216	CbGeAlD
Procainamide—SCN3A—blood—hematologic cancer	0.000737	0.0203	CbGeAlD
Procainamide—SCN5A—blood—hematologic cancer	0.000735	0.0203	CbGeAlD
Procainamide—SCN3A—bone marrow—hematologic cancer	0.000713	0.0197	CbGeAlD
Procainamide—SCN10A—lung—hematologic cancer	0.000709	0.0195	CbGeAlD
Procainamide—ACHE—testis—hematologic cancer	0.0007	0.0193	CbGeAlD
Procainamide—SLC22A3—gonad—hematologic cancer	0.000674	0.0186	CbGeAlD
Procainamide—SCN3A—lung—hematologic cancer	0.000646	0.0178	CbGeAlD
Procainamide—SLC22A4—blood—hematologic cancer	0.000645	0.0178	CbGeAlD
Procainamide—SCN9A—lymph node—hematologic cancer	0.000637	0.0176	CbGeAlD
Procainamide—BCHE—hematopoietic system—hematologic cancer	0.000628	0.0173	CbGeAlD
Procainamide—DNMT1—lymph node—hematologic cancer	0.000625	0.0172	CbGeAlD
Procainamide—SLC22A4—bone marrow—hematologic cancer	0.000624	0.0172	CbGeAlD
Procainamide—SLC22A1—blood—hematologic cancer	0.000615	0.0169	CbGeAlD
Procainamide—SCN3A—testis—hematologic cancer	0.00061	0.0168	CbGeAlD
Procainamide—DNMT1—Vinblastine—Vinorelbine—hematologic cancer	0.000594	0.253	CbGdCrCtD
Procainamide—SLC22A4—lung—hematologic cancer	0.000566	0.0156	CbGeAlD
Procainamide—SLC22A3—lung—hematologic cancer	0.000515	0.0142	CbGeAlD
Procainamide—ACHE—lymph node—hematologic cancer	0.000507	0.014	CbGeAlD
Procainamide—Sunitinib—DAPK1—hematologic cancer	0.000492	0.0902	CrCbGaD
Procainamide—SLC22A3—testis—hematologic cancer	0.000486	0.0134	CbGeAlD
Procainamide—SCN10A—lymph node—hematologic cancer	0.000485	0.0134	CbGeAlD
Procainamide—DNMT1—Vinblastine—Vincristine—hematologic cancer	0.000475	0.202	CbGdCrCtD
Procainamide—Sunitinib—FLT3—hematologic cancer	0.000457	0.0839	CrCbGaD
Procainamide—SCN3A—lymph node—hematologic cancer	0.000442	0.0122	CbGeAlD
Procainamide—SLC22A5—blood—hematologic cancer	0.000427	0.0118	CbGeAlD
Procainamide—CYP2D6—hematopoietic system—hematologic cancer	0.000416	0.0115	CbGeAlD
Procainamide—BCHE—blood—hematologic cancer	0.000416	0.0115	CbGeAlD
Procainamide—Lucanthone—TOP2A—hematologic cancer	0.000407	0.0748	CrCbGaD
Procainamide—BCHE—bone marrow—hematologic cancer	0.000402	0.0111	CbGeAlD
Procainamide—SLC22A4—lymph node—hematologic cancer	0.000387	0.0107	CbGeAlD
Procainamide—SLC22A5—lung—hematologic cancer	0.000374	0.0103	CbGeAlD
Procainamide—BCHE—lung—hematologic cancer	0.000365	0.0101	CbGeAlD
Procainamide—SLC22A5—testis—hematologic cancer	0.000353	0.00974	CbGeAlD
Procainamide—SLC22A3—lymph node—hematologic cancer	0.000352	0.00971	CbGeAlD
Procainamide—Sunitinib—FGR—hematologic cancer	0.000346	0.0636	CrCbGaD
Procainamide—Sunitinib—MAP2K1—hematologic cancer	0.000346	0.0636	CrCbGaD
Procainamide—BCHE—testis—hematologic cancer	0.000344	0.00948	CbGeAlD
Procainamide—Sunitinib—RET—hematologic cancer	0.000295	0.0541	CrCbGaD
Procainamide—CYP2D6—blood—hematologic cancer	0.000276	0.0076	CbGeAlD
Procainamide—Sunitinib—JAK2—hematologic cancer	0.000263	0.0482	CrCbGaD
Procainamide—SLC22A5—lymph node—hematologic cancer	0.000256	0.00706	CbGeAlD
Procainamide—BCHE—lymph node—hematologic cancer	0.000249	0.00687	CbGeAlD
Procainamide—Sunitinib—ALK—hematologic cancer	0.000247	0.0453	CrCbGaD
Procainamide—Sunitinib—CSF1R—hematologic cancer	0.000234	0.0429	CrCbGaD
Procainamide—CYP2D6—testis—hematologic cancer	0.000228	0.00628	CbGeAlD
Procainamide—Probenecid—ABCC3—hematologic cancer	0.000212	0.0388	CrCbGaD
Procainamide—Sunitinib—PDGFRB—hematologic cancer	0.000204	0.0375	CrCbGaD
Procainamide—Sunitinib—PDGFRA—hematologic cancer	0.000199	0.0365	CrCbGaD
Procainamide—Probenecid—SLC22A1—hematologic cancer	0.000147	0.027	CrCbGaD
Procainamide—Sunitinib—KIT—hematologic cancer	0.000146	0.0268	CrCbGaD
Procainamide—Aminohippurate—SLC22A1—hematologic cancer	0.000145	0.0266	CrCbGaD
Procainamide—DNMT1—Budesonide—Dexamethasone—hematologic cancer	0.000135	0.0576	CbGdCrCtD
Procainamide—DNMT1—Budesonide—Betamethasone—hematologic cancer	0.000135	0.0576	CbGdCrCtD
Procainamide—DNMT1—Budesonide—Triamcinolone—hematologic cancer	0.000132	0.0562	CbGdCrCtD
Procainamide—DNMT1—Budesonide—Prednisone—hematologic cancer	0.000125	0.0534	CbGdCrCtD
Procainamide—DNMT1—Budesonide—Prednisolone—hematologic cancer	0.000122	0.0521	CbGdCrCtD
Procainamide—DNMT1—Betamethasone—Dexamethasone—hematologic cancer	8.27e-05	0.0352	CbGdCrCtD
Procainamide—DNMT1—Dexamethasone—Betamethasone—hematologic cancer	8.27e-05	0.0352	CbGdCrCtD
Procainamide—Sunitinib—ABCG2—hematologic cancer	8.09e-05	0.0148	CrCbGaD
Procainamide—DNMT1—Dexamethasone—Triamcinolone—hematologic cancer	8.08e-05	0.0344	CbGdCrCtD
Procainamide—DNMT1—Betamethasone—Triamcinolone—hematologic cancer	8.08e-05	0.0344	CbGdCrCtD
Procainamide—DNMT1—Dexamethasone—Prednisone—hematologic cancer	7.67e-05	0.0327	CbGdCrCtD
Procainamide—DNMT1—Betamethasone—Prednisone—hematologic cancer	7.67e-05	0.0327	CbGdCrCtD
Procainamide—DNMT1—Betamethasone—Prednisolone—hematologic cancer	7.48e-05	0.0319	CbGdCrCtD
Procainamide—DNMT1—Dexamethasone—Prednisolone—hematologic cancer	7.48e-05	0.0319	CbGdCrCtD
Procainamide—Asthenia—Carmustine—hematologic cancer	5.19e-05	0.000289	CcSEcCtD
Procainamide—Vomiting—Vinorelbine—hematologic cancer	5.18e-05	0.000288	CcSEcCtD
Procainamide—Body temperature increased—Gemcitabine—hematologic cancer	5.18e-05	0.000288	CcSEcCtD
Procainamide—Renal failure—Methotrexate—hematologic cancer	5.16e-05	0.000287	CcSEcCtD
Procainamide—Neutropenia—Epirubicin—hematologic cancer	5.15e-05	0.000287	CcSEcCtD
Procainamide—Angioedema—Dexamethasone—hematologic cancer	5.15e-05	0.000287	CcSEcCtD
Procainamide—Angioedema—Betamethasone—hematologic cancer	5.15e-05	0.000287	CcSEcCtD
Procainamide—Diarrhoea—Thalidomide—hematologic cancer	5.15e-05	0.000287	CcSEcCtD
Procainamide—Dizziness—Thiotepa—hematologic cancer	5.15e-05	0.000286	CcSEcCtD
Procainamide—Asthenia—Alitretinoin—hematologic cancer	5.14e-05	0.000286	CcSEcCtD
Procainamide—Hypersensitivity—Vincristine—hematologic cancer	5.09e-05	0.000283	CcSEcCtD
Procainamide—Malaise—Betamethasone—hematologic cancer	5.08e-05	0.000283	CcSEcCtD
Procainamide—Malaise—Dexamethasone—hematologic cancer	5.08e-05	0.000283	CcSEcCtD
Procainamide—Asthenia—Ifosfamide—hematologic cancer	5.08e-05	0.000283	CcSEcCtD
Procainamide—Pruritus—Alitretinoin—hematologic cancer	5.07e-05	0.000282	CcSEcCtD
Procainamide—Eosinophilia—Doxorubicin—hematologic cancer	5.05e-05	0.000281	CcSEcCtD
Procainamide—Benzocaine—ABCB1—hematologic cancer	5.04e-05	0.00926	CrCbGaD
Procainamide—Feeling abnormal—Cisplatin—hematologic cancer	5.03e-05	0.00028	CcSEcCtD
Procainamide—Pruritus—Ifosfamide—hematologic cancer	5.01e-05	0.000279	CcSEcCtD
Procainamide—Shock—Triamcinolone—hematologic cancer	4.99e-05	0.000278	CcSEcCtD
Procainamide—Dizziness—Thalidomide—hematologic cancer	4.98e-05	0.000277	CcSEcCtD
Procainamide—Nausea—Bortezomib—hematologic cancer	4.96e-05	0.000276	CcSEcCtD
Procainamide—Hypersensitivity—Mitoxantrone—hematologic cancer	4.95e-05	0.000275	CcSEcCtD
Procainamide—Hypersensitivity—Irinotecan—hematologic cancer	4.95e-05	0.000275	CcSEcCtD
Procainamide—Asthenia—Vincristine—hematologic cancer	4.95e-05	0.000275	CcSEcCtD
Procainamide—Vomiting—Thiotepa—hematologic cancer	4.95e-05	0.000275	CcSEcCtD
Procainamide—Diarrhoea—Carmustine—hematologic cancer	4.95e-05	0.000275	CcSEcCtD
Procainamide—Nausea—Bleomycin—hematologic cancer	4.92e-05	0.000274	CcSEcCtD
Procainamide—Diarrhoea—Alitretinoin—hematologic cancer	4.9e-05	0.000273	CcSEcCtD
Procainamide—Agranulocytosis—Methotrexate—hematologic cancer	4.9e-05	0.000273	CcSEcCtD
Procainamide—Convulsion—Dexamethasone—hematologic cancer	4.89e-05	0.000272	CcSEcCtD
Procainamide—Convulsion—Betamethasone—hematologic cancer	4.89e-05	0.000272	CcSEcCtD
Procainamide—Decreased appetite—Etoposide—hematologic cancer	4.86e-05	0.00027	CcSEcCtD
Procainamide—Diarrhoea—Ifosfamide—hematologic cancer	4.84e-05	0.000269	CcSEcCtD
Procainamide—Nausea—Vinorelbine—hematologic cancer	4.84e-05	0.000269	CcSEcCtD
Procainamide—Renal failure—Epirubicin—hematologic cancer	4.83e-05	0.000269	CcSEcCtD
Procainamide—Body temperature increased—Cisplatin—hematologic cancer	4.82e-05	0.000268	CcSEcCtD
Procainamide—Asthenia—Mitoxantrone—hematologic cancer	4.82e-05	0.000268	CcSEcCtD
Procainamide—Asthenia—Irinotecan—hematologic cancer	4.82e-05	0.000268	CcSEcCtD
Procainamide—Myalgia—Betamethasone—hematologic cancer	4.8e-05	0.000267	CcSEcCtD
Procainamide—Myalgia—Dexamethasone—hematologic cancer	4.8e-05	0.000267	CcSEcCtD
Procainamide—Vomiting—Thalidomide—hematologic cancer	4.79e-05	0.000266	CcSEcCtD
Procainamide—Dizziness—Carmustine—hematologic cancer	4.78e-05	0.000266	CcSEcCtD
Procainamide—Neutropenia—Doxorubicin—hematologic cancer	4.77e-05	0.000265	CcSEcCtD
Procainamide—Discomfort—Dexamethasone—hematologic cancer	4.74e-05	0.000264	CcSEcCtD
Procainamide—Discomfort—Betamethasone—hematologic cancer	4.74e-05	0.000264	CcSEcCtD
Procainamide—Dizziness—Alitretinoin—hematologic cancer	4.74e-05	0.000263	CcSEcCtD
Procainamide—Diarrhoea—Vincristine—hematologic cancer	4.72e-05	0.000263	CcSEcCtD
Procainamide—Asthenia—Gemcitabine—hematologic cancer	4.7e-05	0.000261	CcSEcCtD
Procainamide—Dizziness—Ifosfamide—hematologic cancer	4.68e-05	0.00026	CcSEcCtD
Procainamide—Pruritus—Gemcitabine—hematologic cancer	4.63e-05	0.000258	CcSEcCtD
Procainamide—Nausea—Thiotepa—hematologic cancer	4.62e-05	0.000257	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	4.62e-05	0.000257	CcSEcCtD
Procainamide—Feeling abnormal—Etoposide—hematologic cancer	4.61e-05	0.000256	CcSEcCtD
Procainamide—Diarrhoea—Irinotecan—hematologic cancer	4.6e-05	0.000256	CcSEcCtD
Procainamide—Diarrhoea—Mitoxantrone—hematologic cancer	4.6e-05	0.000256	CcSEcCtD
Procainamide—Vomiting—Carmustine—hematologic cancer	4.6e-05	0.000256	CcSEcCtD
Procainamide—Agranulocytosis—Epirubicin—hematologic cancer	4.59e-05	0.000255	CcSEcCtD
Procainamide—Gastrointestinal pain—Etoposide—hematologic cancer	4.57e-05	0.000254	CcSEcCtD
Procainamide—Dizziness—Vincristine—hematologic cancer	4.56e-05	0.000254	CcSEcCtD
Procainamide—Ill-defined disorder—Prednisone—hematologic cancer	4.56e-05	0.000253	CcSEcCtD
Procainamide—Vomiting—Alitretinoin—hematologic cancer	4.55e-05	0.000253	CcSEcCtD
Procainamide—Feeling abnormal—Prednisolone—hematologic cancer	4.54e-05	0.000253	CcSEcCtD
Procainamide—Shock—Betamethasone—hematologic cancer	4.53e-05	0.000252	CcSEcCtD
Procainamide—Shock—Dexamethasone—hematologic cancer	4.53e-05	0.000252	CcSEcCtD
Procainamide—Thrombocytopenia—Dexamethasone—hematologic cancer	4.51e-05	0.000251	CcSEcCtD
Procainamide—Thrombocytopenia—Betamethasone—hematologic cancer	4.51e-05	0.000251	CcSEcCtD
Procainamide—Vomiting—Ifosfamide—hematologic cancer	4.5e-05	0.00025	CcSEcCtD
Procainamide—Hypersensitivity—Cisplatin—hematologic cancer	4.5e-05	0.00025	CcSEcCtD
Procainamide—Bradycardia—Epirubicin—hematologic cancer	4.49e-05	0.00025	CcSEcCtD
Procainamide—Angioedema—Prednisone—hematologic cancer	4.49e-05	0.00025	CcSEcCtD
Procainamide—Probenecid—ALB—hematologic cancer	4.48e-05	0.00822	CrCbGaD
Procainamide—Diarrhoea—Gemcitabine—hematologic cancer	4.48e-05	0.000249	CcSEcCtD
Procainamide—Nausea—Thalidomide—hematologic cancer	4.47e-05	0.000249	CcSEcCtD
Procainamide—Renal failure—Doxorubicin—hematologic cancer	4.47e-05	0.000249	CcSEcCtD
Procainamide—Dizziness—Irinotecan—hematologic cancer	4.45e-05	0.000247	CcSEcCtD
Procainamide—Urticaria—Etoposide—hematologic cancer	4.44e-05	0.000247	CcSEcCtD
Procainamide—Malaise—Prednisone—hematologic cancer	4.43e-05	0.000246	CcSEcCtD
Procainamide—Abdominal pain—Etoposide—hematologic cancer	4.42e-05	0.000246	CcSEcCtD
Procainamide—Body temperature increased—Etoposide—hematologic cancer	4.42e-05	0.000246	CcSEcCtD
Procainamide—Vomiting—Vincristine—hematologic cancer	4.39e-05	0.000244	CcSEcCtD
Procainamide—Anorexia—Betamethasone—hematologic cancer	4.39e-05	0.000244	CcSEcCtD
Procainamide—Anorexia—Dexamethasone—hematologic cancer	4.39e-05	0.000244	CcSEcCtD
Procainamide—Urticaria—Prednisolone—hematologic cancer	4.38e-05	0.000244	CcSEcCtD
Procainamide—Asthenia—Cisplatin—hematologic cancer	4.38e-05	0.000244	CcSEcCtD
Procainamide—Cardiac disorder—Methotrexate—hematologic cancer	4.38e-05	0.000243	CcSEcCtD
Procainamide—Hypotension—Betamethasone—hematologic cancer	4.3e-05	0.000239	CcSEcCtD
Procainamide—Hypotension—Dexamethasone—hematologic cancer	4.3e-05	0.000239	CcSEcCtD
Procainamide—Nausea—Carmustine—hematologic cancer	4.3e-05	0.000239	CcSEcCtD
Procainamide—Probenecid—ABCB1—hematologic cancer	4.28e-05	0.00785	CrCbGaD
Procainamide—Vomiting—Mitoxantrone—hematologic cancer	4.27e-05	0.000238	CcSEcCtD
Procainamide—Vomiting—Irinotecan—hematologic cancer	4.27e-05	0.000238	CcSEcCtD
Procainamide—Nausea—Alitretinoin—hematologic cancer	4.25e-05	0.000237	CcSEcCtD
Procainamide—Convulsion—Prednisone—hematologic cancer	4.25e-05	0.000237	CcSEcCtD
Procainamide—Agranulocytosis—Doxorubicin—hematologic cancer	4.24e-05	0.000236	CcSEcCtD
Procainamide—Chills—Methotrexate—hematologic cancer	4.23e-05	0.000235	CcSEcCtD
Procainamide—Aminohippurate—ABCB1—hematologic cancer	4.22e-05	0.00774	CrCbGaD
Procainamide—Nausea—Ifosfamide—hematologic cancer	4.21e-05	0.000234	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Betamethasone—hematologic cancer	4.19e-05	0.000233	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	4.19e-05	0.000233	CcSEcCtD
Procainamide—Arthralgia—Prednisone—hematologic cancer	4.18e-05	0.000233	CcSEcCtD
Procainamide—Myalgia—Prednisone—hematologic cancer	4.18e-05	0.000233	CcSEcCtD
Procainamide—Feeling abnormal—Triamcinolone—hematologic cancer	4.18e-05	0.000232	CcSEcCtD
Procainamide—Diarrhoea—Cisplatin—hematologic cancer	4.18e-05	0.000232	CcSEcCtD
Procainamide—Vomiting—Gemcitabine—hematologic cancer	4.16e-05	0.000232	CcSEcCtD
Procainamide—Bradycardia—Doxorubicin—hematologic cancer	4.16e-05	0.000231	CcSEcCtD
Procainamide—Discomfort—Prednisone—hematologic cancer	4.13e-05	0.00023	CcSEcCtD
Procainamide—Hypersensitivity—Etoposide—hematologic cancer	4.12e-05	0.000229	CcSEcCtD
Procainamide—Lidocaine—ABCB1—hematologic cancer	4.11e-05	0.00755	CrCbGaD
Procainamide—Nausea—Vincristine—hematologic cancer	4.1e-05	0.000228	CcSEcCtD
Procainamide—Cardiac disorder—Epirubicin—hematologic cancer	4.09e-05	0.000228	CcSEcCtD
Procainamide—Flushing—Epirubicin—hematologic cancer	4.09e-05	0.000228	CcSEcCtD
Procainamide—Hypersensitivity—Prednisolone—hematologic cancer	4.06e-05	0.000226	CcSEcCtD
Procainamide—Urticaria—Triamcinolone—hematologic cancer	4.03e-05	0.000224	CcSEcCtD
Procainamide—Dysgeusia—Methotrexate—hematologic cancer	4.02e-05	0.000224	CcSEcCtD
Procainamide—Asthenia—Etoposide—hematologic cancer	4.01e-05	0.000223	CcSEcCtD
Procainamide—Body temperature increased—Triamcinolone—hematologic cancer	4.01e-05	0.000223	CcSEcCtD
Procainamide—Decreased appetite—Dexamethasone—hematologic cancer	4e-05	0.000223	CcSEcCtD
Procainamide—Decreased appetite—Betamethasone—hematologic cancer	4e-05	0.000223	CcSEcCtD
Procainamide—Nausea—Irinotecan—hematologic cancer	3.99e-05	0.000222	CcSEcCtD
Procainamide—Nausea—Mitoxantrone—hematologic cancer	3.99e-05	0.000222	CcSEcCtD
Procainamide—Chills—Epirubicin—hematologic cancer	3.96e-05	0.00022	CcSEcCtD
Procainamide—Pruritus—Etoposide—hematologic cancer	3.96e-05	0.00022	CcSEcCtD
Procainamide—Shock—Prednisone—hematologic cancer	3.94e-05	0.000219	CcSEcCtD
Procainamide—Nausea—Gemcitabine—hematologic cancer	3.89e-05	0.000216	CcSEcCtD
Procainamide—Vomiting—Cisplatin—hematologic cancer	3.88e-05	0.000216	CcSEcCtD
Procainamide—Diarrhoea—Etoposide—hematologic cancer	3.83e-05	0.000213	CcSEcCtD
Procainamide—Anorexia—Prednisone—hematologic cancer	3.82e-05	0.000212	CcSEcCtD
Procainamide—Ill-defined disorder—Methotrexate—hematologic cancer	3.81e-05	0.000212	CcSEcCtD
Procainamide—Feeling abnormal—Dexamethasone—hematologic cancer	3.79e-05	0.000211	CcSEcCtD
Procainamide—Feeling abnormal—Betamethasone—hematologic cancer	3.79e-05	0.000211	CcSEcCtD
Procainamide—Cardiac disorder—Doxorubicin—hematologic cancer	3.79e-05	0.000211	CcSEcCtD
Procainamide—Flushing—Doxorubicin—hematologic cancer	3.79e-05	0.000211	CcSEcCtD
Procainamide—Gastrointestinal pain—Betamethasone—hematologic cancer	3.76e-05	0.000209	CcSEcCtD
Procainamide—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.76e-05	0.000209	CcSEcCtD
Procainamide—Dysgeusia—Epirubicin—hematologic cancer	3.76e-05	0.000209	CcSEcCtD
Procainamide—Hypersensitivity—Triamcinolone—hematologic cancer	3.74e-05	0.000208	CcSEcCtD
Procainamide—Malaise—Methotrexate—hematologic cancer	3.7e-05	0.000206	CcSEcCtD
Procainamide—Dizziness—Etoposide—hematologic cancer	3.7e-05	0.000206	CcSEcCtD
Procainamide—Chills—Doxorubicin—hematologic cancer	3.66e-05	0.000204	CcSEcCtD
Procainamide—Urticaria—Betamethasone—hematologic cancer	3.66e-05	0.000203	CcSEcCtD
Procainamide—Urticaria—Dexamethasone—hematologic cancer	3.66e-05	0.000203	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.65e-05	0.000203	CcSEcCtD
Procainamide—Dizziness—Prednisolone—hematologic cancer	3.65e-05	0.000203	CcSEcCtD
Procainamide—Asthenia—Triamcinolone—hematologic cancer	3.64e-05	0.000202	CcSEcCtD
Procainamide—Abdominal pain—Betamethasone—hematologic cancer	3.64e-05	0.000202	CcSEcCtD
Procainamide—Abdominal pain—Dexamethasone—hematologic cancer	3.64e-05	0.000202	CcSEcCtD
Procainamide—Body temperature increased—Betamethasone—hematologic cancer	3.64e-05	0.000202	CcSEcCtD
Procainamide—Body temperature increased—Dexamethasone—hematologic cancer	3.64e-05	0.000202	CcSEcCtD
Procainamide—Nausea—Cisplatin—hematologic cancer	3.63e-05	0.000202	CcSEcCtD
Procainamide—Pruritus—Triamcinolone—hematologic cancer	3.59e-05	0.0002	CcSEcCtD
Procainamide—Ill-defined disorder—Epirubicin—hematologic cancer	3.56e-05	0.000198	CcSEcCtD
Procainamide—Convulsion—Methotrexate—hematologic cancer	3.56e-05	0.000198	CcSEcCtD
Procainamide—Vomiting—Etoposide—hematologic cancer	3.56e-05	0.000198	CcSEcCtD
Procainamide—Myalgia—Methotrexate—hematologic cancer	3.49e-05	0.000194	CcSEcCtD
Procainamide—Arthralgia—Methotrexate—hematologic cancer	3.49e-05	0.000194	CcSEcCtD
Procainamide—Decreased appetite—Prednisone—hematologic cancer	3.48e-05	0.000194	CcSEcCtD
Procainamide—Dysgeusia—Doxorubicin—hematologic cancer	3.48e-05	0.000194	CcSEcCtD
Procainamide—Malaise—Epirubicin—hematologic cancer	3.46e-05	0.000193	CcSEcCtD
Procainamide—Discomfort—Methotrexate—hematologic cancer	3.45e-05	0.000192	CcSEcCtD
Procainamide—Confusional state—Methotrexate—hematologic cancer	3.38e-05	0.000188	CcSEcCtD
Procainamide—Sunitinib—ABCB1—hematologic cancer	3.37e-05	0.00618	CrCbGaD
Procainamide—Dizziness—Triamcinolone—hematologic cancer	3.35e-05	0.000187	CcSEcCtD
Procainamide—Convulsion—Epirubicin—hematologic cancer	3.33e-05	0.000185	CcSEcCtD
Procainamide—Nausea—Etoposide—hematologic cancer	3.32e-05	0.000185	CcSEcCtD
Procainamide—Feeling abnormal—Prednisone—hematologic cancer	3.3e-05	0.000184	CcSEcCtD
Procainamide—Asthenia—Dexamethasone—hematologic cancer	3.3e-05	0.000184	CcSEcCtD
Procainamide—Asthenia—Betamethasone—hematologic cancer	3.3e-05	0.000184	CcSEcCtD
Procainamide—Ill-defined disorder—Doxorubicin—hematologic cancer	3.3e-05	0.000183	CcSEcCtD
Procainamide—Thrombocytopenia—Methotrexate—hematologic cancer	3.28e-05	0.000182	CcSEcCtD
Procainamide—Gastrointestinal pain—Prednisone—hematologic cancer	3.28e-05	0.000182	CcSEcCtD
Procainamide—Nausea—Prednisolone—hematologic cancer	3.28e-05	0.000182	CcSEcCtD
Procainamide—Myalgia—Epirubicin—hematologic cancer	3.27e-05	0.000182	CcSEcCtD
Procainamide—Arthralgia—Epirubicin—hematologic cancer	3.27e-05	0.000182	CcSEcCtD
Procainamide—Pruritus—Dexamethasone—hematologic cancer	3.26e-05	0.000181	CcSEcCtD
Procainamide—Pruritus—Betamethasone—hematologic cancer	3.26e-05	0.000181	CcSEcCtD
Procainamide—Discomfort—Epirubicin—hematologic cancer	3.23e-05	0.00018	CcSEcCtD
Procainamide—Vomiting—Triamcinolone—hematologic cancer	3.22e-05	0.000179	CcSEcCtD
Procainamide—Malaise—Doxorubicin—hematologic cancer	3.2e-05	0.000178	CcSEcCtD
Procainamide—Anorexia—Methotrexate—hematologic cancer	3.19e-05	0.000178	CcSEcCtD
Procainamide—Urticaria—Prednisone—hematologic cancer	3.18e-05	0.000177	CcSEcCtD
Procainamide—Abdominal pain—Prednisone—hematologic cancer	3.17e-05	0.000176	CcSEcCtD
Procainamide—Body temperature increased—Prednisone—hematologic cancer	3.17e-05	0.000176	CcSEcCtD
Procainamide—Confusional state—Epirubicin—hematologic cancer	3.16e-05	0.000176	CcSEcCtD
Procainamide—Diarrhoea—Betamethasone—hematologic cancer	3.15e-05	0.000175	CcSEcCtD
Procainamide—Diarrhoea—Dexamethasone—hematologic cancer	3.15e-05	0.000175	CcSEcCtD
Procainamide—Hypotension—Methotrexate—hematologic cancer	3.13e-05	0.000174	CcSEcCtD
Procainamide—Shock—Epirubicin—hematologic cancer	3.08e-05	0.000172	CcSEcCtD
Procainamide—Convulsion—Doxorubicin—hematologic cancer	3.08e-05	0.000171	CcSEcCtD
Procainamide—Thrombocytopenia—Epirubicin—hematologic cancer	3.07e-05	0.000171	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.05e-05	0.00017	CcSEcCtD
Procainamide—Dizziness—Betamethasone—hematologic cancer	3.04e-05	0.000169	CcSEcCtD
Procainamide—Dizziness—Dexamethasone—hematologic cancer	3.04e-05	0.000169	CcSEcCtD
Procainamide—Myalgia—Doxorubicin—hematologic cancer	3.03e-05	0.000168	CcSEcCtD
Procainamide—Arthralgia—Doxorubicin—hematologic cancer	3.03e-05	0.000168	CcSEcCtD
Procainamide—Nausea—Triamcinolone—hematologic cancer	3.01e-05	0.000168	CcSEcCtD
Procainamide—Discomfort—Doxorubicin—hematologic cancer	2.99e-05	0.000166	CcSEcCtD
Procainamide—Anorexia—Epirubicin—hematologic cancer	2.99e-05	0.000166	CcSEcCtD
Procainamide—Hypersensitivity—Prednisone—hematologic cancer	2.95e-05	0.000164	CcSEcCtD
Procainamide—Hypotension—Epirubicin—hematologic cancer	2.93e-05	0.000163	CcSEcCtD
Procainamide—Vomiting—Betamethasone—hematologic cancer	2.93e-05	0.000163	CcSEcCtD
Procainamide—Vomiting—Dexamethasone—hematologic cancer	2.93e-05	0.000163	CcSEcCtD
Procainamide—Confusional state—Doxorubicin—hematologic cancer	2.92e-05	0.000163	CcSEcCtD
Procainamide—Decreased appetite—Methotrexate—hematologic cancer	2.91e-05	0.000162	CcSEcCtD
Procainamide—Asthenia—Prednisone—hematologic cancer	2.88e-05	0.00016	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.86e-05	0.000159	CcSEcCtD
Procainamide—Shock—Doxorubicin—hematologic cancer	2.85e-05	0.000159	CcSEcCtD
Procainamide—Thrombocytopenia—Doxorubicin—hematologic cancer	2.84e-05	0.000158	CcSEcCtD
Procainamide—Pruritus—Prednisone—hematologic cancer	2.84e-05	0.000158	CcSEcCtD
Procainamide—Anorexia—Doxorubicin—hematologic cancer	2.76e-05	0.000154	CcSEcCtD
Procainamide—Feeling abnormal—Methotrexate—hematologic cancer	2.76e-05	0.000154	CcSEcCtD
Procainamide—Diarrhoea—Prednisone—hematologic cancer	2.74e-05	0.000153	CcSEcCtD
Procainamide—Gastrointestinal pain—Methotrexate—hematologic cancer	2.74e-05	0.000152	CcSEcCtD
Procainamide—Nausea—Betamethasone—hematologic cancer	2.73e-05	0.000152	CcSEcCtD
Procainamide—Nausea—Dexamethasone—hematologic cancer	2.73e-05	0.000152	CcSEcCtD
Procainamide—Decreased appetite—Epirubicin—hematologic cancer	2.72e-05	0.000152	CcSEcCtD
Procainamide—Hypotension—Doxorubicin—hematologic cancer	2.71e-05	0.000151	CcSEcCtD
Procainamide—Urticaria—Methotrexate—hematologic cancer	2.66e-05	0.000148	CcSEcCtD
Procainamide—Dizziness—Prednisone—hematologic cancer	2.65e-05	0.000147	CcSEcCtD
Procainamide—Abdominal pain—Methotrexate—hematologic cancer	2.65e-05	0.000147	CcSEcCtD
Procainamide—Body temperature increased—Methotrexate—hematologic cancer	2.65e-05	0.000147	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.64e-05	0.000147	CcSEcCtD
Procainamide—Feeling abnormal—Epirubicin—hematologic cancer	2.58e-05	0.000144	CcSEcCtD
Procainamide—Gastrointestinal pain—Epirubicin—hematologic cancer	2.56e-05	0.000143	CcSEcCtD
Procainamide—Vomiting—Prednisone—hematologic cancer	2.55e-05	0.000142	CcSEcCtD
Procainamide—Decreased appetite—Doxorubicin—hematologic cancer	2.52e-05	0.00014	CcSEcCtD
Procainamide—Urticaria—Epirubicin—hematologic cancer	2.49e-05	0.000139	CcSEcCtD
Procainamide—Abdominal pain—Epirubicin—hematologic cancer	2.48e-05	0.000138	CcSEcCtD
Procainamide—Body temperature increased—Epirubicin—hematologic cancer	2.48e-05	0.000138	CcSEcCtD
Procainamide—Hypersensitivity—Methotrexate—hematologic cancer	2.47e-05	0.000137	CcSEcCtD
Procainamide—Asthenia—Methotrexate—hematologic cancer	2.4e-05	0.000134	CcSEcCtD
Procainamide—Feeling abnormal—Doxorubicin—hematologic cancer	2.39e-05	0.000133	CcSEcCtD
Procainamide—Nausea—Prednisone—hematologic cancer	2.38e-05	0.000132	CcSEcCtD
Procainamide—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.37e-05	0.000132	CcSEcCtD
Procainamide—Pruritus—Methotrexate—hematologic cancer	2.37e-05	0.000132	CcSEcCtD
Procainamide—Hypersensitivity—Epirubicin—hematologic cancer	2.31e-05	0.000128	CcSEcCtD
Procainamide—Urticaria—Doxorubicin—hematologic cancer	2.3e-05	0.000128	CcSEcCtD
Procainamide—Abdominal pain—Doxorubicin—hematologic cancer	2.29e-05	0.000128	CcSEcCtD
Procainamide—Body temperature increased—Doxorubicin—hematologic cancer	2.29e-05	0.000128	CcSEcCtD
Procainamide—Diarrhoea—Methotrexate—hematologic cancer	2.29e-05	0.000127	CcSEcCtD
Procainamide—Asthenia—Epirubicin—hematologic cancer	2.25e-05	0.000125	CcSEcCtD
Procainamide—Pruritus—Epirubicin—hematologic cancer	2.22e-05	0.000123	CcSEcCtD
Procainamide—Dizziness—Methotrexate—hematologic cancer	2.21e-05	0.000123	CcSEcCtD
Procainamide—Diarrhoea—Epirubicin—hematologic cancer	2.14e-05	0.000119	CcSEcCtD
Procainamide—Hypersensitivity—Doxorubicin—hematologic cancer	2.14e-05	0.000119	CcSEcCtD
Procainamide—Vomiting—Methotrexate—hematologic cancer	2.13e-05	0.000118	CcSEcCtD
Procainamide—Asthenia—Doxorubicin—hematologic cancer	2.08e-05	0.000116	CcSEcCtD
Procainamide—Dizziness—Epirubicin—hematologic cancer	2.07e-05	0.000115	CcSEcCtD
Procainamide—Pruritus—Doxorubicin—hematologic cancer	2.05e-05	0.000114	CcSEcCtD
Procainamide—Vomiting—Epirubicin—hematologic cancer	1.99e-05	0.000111	CcSEcCtD
Procainamide—Nausea—Methotrexate—hematologic cancer	1.99e-05	0.000111	CcSEcCtD
Procainamide—Diarrhoea—Doxorubicin—hematologic cancer	1.98e-05	0.00011	CcSEcCtD
Procainamide—Dizziness—Doxorubicin—hematologic cancer	1.92e-05	0.000107	CcSEcCtD
Procainamide—Nausea—Epirubicin—hematologic cancer	1.86e-05	0.000104	CcSEcCtD
Procainamide—Vomiting—Doxorubicin—hematologic cancer	1.84e-05	0.000103	CcSEcCtD
Procainamide—Nausea—Doxorubicin—hematologic cancer	1.72e-05	9.58e-05	CcSEcCtD
Procainamide—CHRM2—GPCR downstream signaling—JAK1—hematologic cancer	4.71e-06	4.35e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—RAC2—hematologic cancer	4.7e-06	4.34e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—DKK1—hematologic cancer	4.66e-06	4.31e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—GSTM1—hematologic cancer	4.66e-06	4.31e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—NCOR1—hematologic cancer	4.66e-06	4.31e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—STAT5B—hematologic cancer	4.62e-06	4.28e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	4.59e-06	4.24e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—CYCS—hematologic cancer	4.58e-06	4.24e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—HSP90AA1—hematologic cancer	4.55e-06	4.21e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—IDH2—hematologic cancer	4.55e-06	4.21e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—HMMR—hematologic cancer	4.55e-06	4.21e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—GSTP1—hematologic cancer	4.52e-06	4.18e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—CD44—hematologic cancer	4.51e-06	4.17e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—NQO1—hematologic cancer	4.51e-06	4.17e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—ADCY7—hematologic cancer	4.49e-06	4.15e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CSF2—hematologic cancer	4.43e-06	4.1e-05	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—HRAS—hematologic cancer	4.41e-06	4.08e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—IL2RA—hematologic cancer	4.39e-06	4.06e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PIK3CG—hematologic cancer	4.39e-06	4.06e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	4.37e-06	4.05e-05	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—AKT1—hematologic cancer	4.37e-06	4.04e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—XIAP—hematologic cancer	4.37e-06	4.04e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—ABCB1—hematologic cancer	4.28e-06	3.96e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ARNTL—hematologic cancer	4.28e-06	3.96e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PRKCG—hematologic cancer	4.27e-06	3.95e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—JAK1—hematologic cancer	4.27e-06	3.95e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—CYCS—hematologic cancer	4.27e-06	3.95e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SMARCA4—hematologic cancer	4.25e-06	3.94e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SH2B3—hematologic cancer	4.25e-06	3.94e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—HSP90AA1—hematologic cancer	4.24e-06	3.92e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—GZMB—hematologic cancer	4.23e-06	3.91e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CA9—hematologic cancer	4.16e-06	3.85e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ACP5—hematologic cancer	4.16e-06	3.85e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—GSTM1—hematologic cancer	4.15e-06	3.84e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—NCOR1—hematologic cancer	4.15e-06	3.84e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CTNNA1—hematologic cancer	4.13e-06	3.82e-05	CbGpPWpGaD
Procainamide—DNMT1—Gene Expression—AKT1—hematologic cancer	4.12e-06	3.81e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—MTHFR—hematologic cancer	4.12e-06	3.81e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NCOR2—hematologic cancer	4.11e-06	3.8e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HSPB1—hematologic cancer	4.1e-06	3.8e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—EIF4EBP1—hematologic cancer	4.1e-06	3.8e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CCL3—hematologic cancer	4.1e-06	3.8e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—CREBBP—hematologic cancer	4.07e-06	3.77e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PTHLH—hematologic cancer	4.06e-06	3.75e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SDC1—hematologic cancer	4.06e-06	3.75e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—GSTP1—hematologic cancer	4.04e-06	3.73e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—IL2RA—hematologic cancer	3.99e-06	3.69e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PTGER4—hematologic cancer	3.95e-06	3.65e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—LCK—hematologic cancer	3.93e-06	3.64e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—IDH1—hematologic cancer	3.91e-06	3.62e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ABCC3—hematologic cancer	3.87e-06	3.58e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—TXN—hematologic cancer	3.87e-06	3.58e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GSTO1—hematologic cancer	3.87e-06	3.58e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PIK3CD—hematologic cancer	3.86e-06	3.57e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—H3F3A—hematologic cancer	3.85e-06	3.56e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—ABCB1—hematologic cancer	3.82e-06	3.53e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—ALB—hematologic cancer	3.81e-06	3.53e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—SPHK1—hematologic cancer	3.78e-06	3.5e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—GSTP1—hematologic cancer	3.76e-06	3.48e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PRKCZ—hematologic cancer	3.75e-06	3.46e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—GSTM1—hematologic cancer	3.71e-06	3.43e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—NCOR1—hematologic cancer	3.71e-06	3.43e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—MTHFR—hematologic cancer	3.67e-06	3.4e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—PIK3CG—hematologic cancer	3.66e-06	3.39e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PIK3R1—hematologic cancer	3.65e-06	3.37e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—UGT1A1—hematologic cancer	3.64e-06	3.36e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.63e-06	3.35e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PARP1—hematologic cancer	3.62e-06	3.35e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—ABCB1—hematologic cancer	3.56e-06	3.29e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—FBXW7—hematologic cancer	3.56e-06	3.29e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—SLC22A1—hematologic cancer	3.54e-06	3.27e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CRABP1—hematologic cancer	3.54e-06	3.27e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CXCR4—hematologic cancer	3.49e-06	3.23e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HDAC2—hematologic cancer	3.49e-06	3.23e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—GSTM1—hematologic cancer	3.46e-06	3.2e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—NCOR1—hematologic cancer	3.46e-06	3.2e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PIK3CG—hematologic cancer	3.46e-06	3.2e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ALOX5—hematologic cancer	3.45e-06	3.19e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CBL—hematologic cancer	3.4e-06	3.15e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PIK3CB—hematologic cancer	3.37e-06	3.11e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IL3—hematologic cancer	3.37e-06	3.11e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NUP98—hematologic cancer	3.34e-06	3.09e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PIK3CG—hematologic cancer	3.32e-06	3.08e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PTPN1—hematologic cancer	3.31e-06	3.06e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—MTHFR—hematologic cancer	3.28e-06	3.03e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PTPN11—hematologic cancer	3.27e-06	3.02e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—RASGRP1—hematologic cancer	3.26e-06	3.01e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SYK—hematologic cancer	3.24e-06	3e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HSP90AA1—hematologic cancer	3.24e-06	3e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NCOA3—hematologic cancer	3.24e-06	3e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ADCY7—hematologic cancer	3.24e-06	3e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.24e-06	2.99e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—PIK3CD—hematologic cancer	3.22e-06	2.98e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NUP214—hematologic cancer	3.22e-06	2.98e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—CREBBP—hematologic cancer	3.21e-06	2.97e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CREB1—hematologic cancer	3.16e-06	2.93e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—MTR—hematologic cancer	3.15e-06	2.92e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ABCG2—hematologic cancer	3.15e-06	2.92e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—STAT1—hematologic cancer	3.13e-06	2.89e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CCL2—hematologic cancer	3.1e-06	2.86e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ENO2—hematologic cancer	3.09e-06	2.86e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—IL6R—hematologic cancer	3.09e-06	2.86e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PIK3CG—hematologic cancer	3.08e-06	2.85e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—MTHFR—hematologic cancer	3.06e-06	2.83e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PIK3CD—hematologic cancer	3.04e-06	2.81e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—PIK3R1—hematologic cancer	3.04e-06	2.81e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—ALB—hematologic cancer	3e-06	2.78e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GSTT1—hematologic cancer	3e-06	2.77e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—JAK2—hematologic cancer	2.95e-06	2.73e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—MAP2K1—hematologic cancer	2.94e-06	2.72e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—SDC1—hematologic cancer	2.93e-06	2.71e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—GRB2—hematologic cancer	2.93e-06	2.71e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PIK3CD—hematologic cancer	2.92e-06	2.7e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PDGFA—hematologic cancer	2.92e-06	2.7e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PTEN—hematologic cancer	2.91e-06	2.69e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—KITLG—hematologic cancer	2.88e-06	2.66e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PIK3R1—hematologic cancer	2.87e-06	2.65e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—CREBBP—hematologic cancer	2.86e-06	2.65e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—STAT5A—hematologic cancer	2.81e-06	2.6e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—PIK3CB—hematologic cancer	2.81e-06	2.59e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CDKN2B—hematologic cancer	2.79e-06	2.58e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—EP300—hematologic cancer	2.77e-06	2.57e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PIK3R1—hematologic cancer	2.76e-06	2.55e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PIK3CG—hematologic cancer	2.75e-06	2.55e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PIK3CD—hematologic cancer	2.71e-06	2.51e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CD86—hematologic cancer	2.7e-06	2.49e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—JAK2—hematologic cancer	2.68e-06	2.48e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—ALB—hematologic cancer	2.68e-06	2.48e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HES1—hematologic cancer	2.66e-06	2.46e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PIK3CB—hematologic cancer	2.65e-06	2.45e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NCOR1—hematologic cancer	2.65e-06	2.45e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CSF2—hematologic cancer	2.62e-06	2.42e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—FGF1—hematologic cancer	2.62e-06	2.42e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—FOXO1—hematologic cancer	2.58e-06	2.38e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—IL2—hematologic cancer	2.58e-06	2.38e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PDGFRB—hematologic cancer	2.57e-06	2.38e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PIK3CG—hematologic cancer	2.57e-06	2.38e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PIK3R1—hematologic cancer	2.56e-06	2.37e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—CREBBP—hematologic cancer	2.55e-06	2.36e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PIK3CB—hematologic cancer	2.55e-06	2.36e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PDGFRA—hematologic cancer	2.53e-06	2.34e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PRKCG—hematologic cancer	2.52e-06	2.33e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—JAK1—hematologic cancer	2.52e-06	2.33e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CD44—hematologic cancer	2.49e-06	2.3e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NQO1—hematologic cancer	2.49e-06	2.3e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PIK3CD—hematologic cancer	2.42e-06	2.24e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—ALB—hematologic cancer	2.39e-06	2.21e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—CREBBP—hematologic cancer	2.38e-06	2.2e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PIK3CB—hematologic cancer	2.36e-06	2.19e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CYCS—hematologic cancer	2.36e-06	2.18e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IL2RA—hematologic cancer	2.36e-06	2.18e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	2.34e-06	2.17e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—IL2—hematologic cancer	2.34e-06	2.16e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TERT—hematologic cancer	2.33e-06	2.16e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PTEN—hematologic cancer	2.29e-06	2.12e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PIK3R1—hematologic cancer	2.29e-06	2.12e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PDGFB—hematologic cancer	2.28e-06	2.1e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PIK3CD—hematologic cancer	2.26e-06	2.09e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—ALB—hematologic cancer	2.23e-06	2.06e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TSC2—hematologic cancer	2.22e-06	2.06e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—EP300—hematologic cancer	2.18e-06	2.02e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—FGFR3—hematologic cancer	2.14e-06	1.98e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PIK3R1—hematologic cancer	2.13e-06	1.97e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MAPK14—hematologic cancer	2.12e-06	1.96e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PIK3CB—hematologic cancer	2.11e-06	1.95e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GSTP1—hematologic cancer	2.08e-06	1.92e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—ESR1—hematologic cancer	2.08e-06	1.92e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—FN1—hematologic cancer	2.05e-06	1.9e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PIK3CA—hematologic cancer	2.05e-06	1.9e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PTEN—hematologic cancer	2.04e-06	1.89e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—BAD—hematologic cancer	2.03e-06	1.88e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NFKBIA—hematologic cancer	2.03e-06	1.88e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NOTCH1—hematologic cancer	2.01e-06	1.86e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CD80—hematologic cancer	1.97e-06	1.82e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PIK3CB—hematologic cancer	1.97e-06	1.82e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ABCB1—hematologic cancer	1.97e-06	1.82e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PIK3CG—hematologic cancer	1.96e-06	1.82e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—KIT—hematologic cancer	1.96e-06	1.82e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—NRAS—hematologic cancer	1.96e-06	1.82e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—EP300—hematologic cancer	1.95e-06	1.8e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PTPN11—hematologic cancer	1.93e-06	1.78e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GSTM1—hematologic cancer	1.91e-06	1.77e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NCOR1—hematologic cancer	1.91e-06	1.77e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—MAPK3—hematologic cancer	1.88e-06	1.74e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CREB1—hematologic cancer	1.87e-06	1.73e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—BRAF—hematologic cancer	1.85e-06	1.71e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CCL2—hematologic cancer	1.83e-06	1.69e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PTEN—hematologic cancer	1.82e-06	1.69e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IL6R—hematologic cancer	1.82e-06	1.69e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CREBBP—hematologic cancer	1.82e-06	1.68e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—EP300—hematologic cancer	1.74e-06	1.61e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MAP2K1—hematologic cancer	1.74e-06	1.61e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PIK3CD—hematologic cancer	1.73e-06	1.6e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—PIK3CA—hematologic cancer	1.71e-06	1.58e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PTEN—hematologic cancer	1.7e-06	1.57e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—KRAS—hematologic cancer	1.69e-06	1.56e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—MTHFR—hematologic cancer	1.69e-06	1.56e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—AKT1—hematologic cancer	1.68e-06	1.55e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—FGF2—hematologic cancer	1.65e-06	1.53e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PIK3R1—hematologic cancer	1.63e-06	1.51e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—EP300—hematologic cancer	1.62e-06	1.5e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PIK3CA—hematologic cancer	1.62e-06	1.49e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—JAK2—hematologic cancer	1.58e-06	1.47e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PIK3CA—hematologic cancer	1.55e-06	1.44e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MDM2—hematologic cancer	1.55e-06	1.43e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PIK3CB—hematologic cancer	1.5e-06	1.39e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MTOR—hematologic cancer	1.5e-06	1.39e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PIK3CA—hematologic cancer	1.44e-06	1.33e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—HRAS—hematologic cancer	1.44e-06	1.33e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PIK3CG—hematologic cancer	1.42e-06	1.31e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CDKN1B—hematologic cancer	1.41e-06	1.31e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—AKT1—hematologic cancer	1.4e-06	1.29e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CASP3—hematologic cancer	1.38e-06	1.28e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IL2—hematologic cancer	1.38e-06	1.28e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—IL6—hematologic cancer	1.38e-06	1.27e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CCND1—hematologic cancer	1.35e-06	1.25e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—JUN—hematologic cancer	1.34e-06	1.24e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—AKT1—hematologic cancer	1.32e-06	1.22e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CREBBP—hematologic cancer	1.31e-06	1.22e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CDKN1A—hematologic cancer	1.3e-06	1.21e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PTEN—hematologic cancer	1.3e-06	1.2e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PIK3CA—hematologic cancer	1.29e-06	1.19e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MAPK8—hematologic cancer	1.27e-06	1.18e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—AKT1—hematologic cancer	1.27e-06	1.17e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.25e-06	1.15e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—EP300—hematologic cancer	1.24e-06	1.15e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ALB—hematologic cancer	1.23e-06	1.14e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SRC—hematologic cancer	1.21e-06	1.12e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PIK3CA—hematologic cancer	1.2e-06	1.11e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.18e-06	1.09e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—AKT1—hematologic cancer	1.18e-06	1.09e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—VEGFA—hematologic cancer	1.17e-06	1.09e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—STAT3—hematologic cancer	1.16e-06	1.08e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NRAS—hematologic cancer	1.16e-06	1.07e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MAPK3—hematologic cancer	1.11e-06	1.03e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.09e-06	1.01e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MYC—hematologic cancer	1.08e-06	1e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TGFB1—hematologic cancer	1.08e-06	9.97e-06	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—AKT1—hematologic cancer	1.05e-06	9.72e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—KRAS—hematologic cancer	9.99e-07	9.24e-06	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—AKT1—hematologic cancer	9.8e-07	9.06e-06	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PTEN—hematologic cancer	9.39e-07	8.69e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PIK3CA—hematologic cancer	9.17e-07	8.49e-06	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—EP300—hematologic cancer	8.96e-07	8.28e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TP53—hematologic cancer	8.88e-07	8.21e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HRAS—hematologic cancer	8.49e-07	7.85e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IL6—hematologic cancer	8.12e-07	7.51e-06	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—AKT1—hematologic cancer	7.49e-07	6.93e-06	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PIK3CA—hematologic cancer	6.62e-07	6.13e-06	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—AKT1—hematologic cancer	5.41e-07	5.01e-06	CbGpPWpGaD
